Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials

Lund, S. S., Sattar, N., Salsali, A., Neubacher, D., & Ginsberg, H. N. (2021). Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials. Diabetes, Obesity and Metabolism, 23(12), 2763–2774. Portico. https://doi.org/10.1111/dom.14534
Authors:
Søren S. Lund
Naveed Sattar
Afshin Salsali
Dietmar Neubacher
Henry N. Ginsberg
Affiliated Authors:
Henry N. Ginsberg
Columbia Affiliation:
Author Keywords:
antidiabetes drug
clinical trial
empagliflozin
sglt2 inhibitor
type 2 diabetes
elink
Publication Type:
Article
Unique ID:
10.1111/dom.14534
PMID:
34463415
DOI:
10.1111/dom.14534
Journal:
Diabetes, Obesity and Metabolism
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record

Record Created: